A Study to Evaluate Brain Natriuretic Peptides for the Avoidance of Treatment-Related Heart Failure in Breast Cancer Survivors

Overview

About this study

The purpose of this study is to determine if Brain Natriuretic Peptide (NT-pro-BNP) values increase over time in breast cancer survivors and correlate with cardiac dysfunction. This study will define the average NT-pro-B-natriuretic peptide values in female breast cancer patients 1, 2, 3, 4, and 5 years out from anthracycline-based chemotherapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Female
≥ 18 years
Non-metastatic breast cancer
At least 1 year after completion of cancer therapy with anthracycline-based chemotherapy
No prior history of Heart failure or cardiomyopathy
Ability to provide informed consent

Exclusion Criteria

History of heart failure or cardiomyopathy
Inability or unwillingness of individual or legal guardian/representative to give written informed consent

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Joerg Herrmann, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Joerg Herrmann, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials